Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $7.20.

PYXS has been the subject of a number of recent analyst reports. Stephens raised their price objective on Pyxis Oncology from $5.00 to $8.00 and gave the stock an “overweight” rating in a research report on Monday, November 24th. Wall Street Zen lowered Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Sunday. HC Wainwright increased their price target on Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Finally, Royal Bank Of Canada dropped their price target on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Thursday, December 18th.

Hedge Funds Weigh In On Pyxis Oncology

Hedge funds have recently made changes to their positions in the company. Maia Wealth LLC purchased a new position in Pyxis Oncology in the 4th quarter worth $25,000. Engineers Gate Manager LP purchased a new stake in Pyxis Oncology during the 4th quarter valued at about $26,000. Fox Run Management L.L.C. acquired a new position in shares of Pyxis Oncology in the fourth quarter valued at about $26,000. Catalyst Funds Management Pty Ltd acquired a new position in shares of Pyxis Oncology in the second quarter valued at about $26,000. Finally, Avanza Fonder AB purchased a new position in shares of Pyxis Oncology in the fourth quarter worth about $31,000. 39.09% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology Trading Down 3.0%

NASDAQ PYXS opened at $1.62 on Wednesday. The firm’s fifty day simple moving average is $1.54 and its two-hundred day simple moving average is $2.51. The firm has a market capitalization of $100.86 million, a P/E ratio of -1.01 and a beta of 1.45. Pyxis Oncology has a 12-month low of $0.83 and a 12-month high of $5.55.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.